专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005037206A3 ANTI-CANCER COMPOUNDS AND METHODS OF USE THEREOF 审中-公开
标题翻译：抗癌化合物及其使用方法
公开(公告)号：WO2005037206A3
公开(公告)日：2005-08-04
申请号：PCT/US2004033697
申请日：2004-10-14
申请人： GTX INC , STEINER MITCHELL S , MILLER DUANE D , VEVERKA KAREN A , BARRETT CHRISTINA , HONG SEOUNG-SOO
发明人： STEINER MITCHELL S , MILLER DUANE D , VEVERKA KAREN A , BARRETT CHRISTINA , HONG SEOUNG-SOO
IPC分类号： A61K20060101 , A61K31/165 , A61K31/277 , A61K31/325 , A61K39/395 , C07C235/24 , C07C255/60 , C07C271/24 , C07C309/87 , C07C317/40 , C07C323/60 , C07D207/448 , C07F9/09
CPC分类号： C07D207/448 , C07C215/76 , C07C235/16 , C07C235/24 , C07C255/60 , C07C271/24 , C07C309/87 , C07C317/46 , C07C323/60 , C07D233/74
摘要： The present invention relates to a novel class of anti-cancer compounds which selectively target androgen receptor (AR)-expressing cancer, cells, such as prostate cancer cells and breast cancer cells, These agents comprise an androgen receptor (AR) binding moiety, which selectively tar-gets the compounds to (AR)-expressing cancer cells, and a cytotoxic alkylating moiety, such as a nitrogen mustard moiety, The inherent high density expression of the androgen receptor in certain cancers, such as prostate cancer and breast cancer, is thus used as a tool to selectively increase the intracellular concentration of cytotoxic compounds, such as alkylating agents, e,g. DNA alkylating agents, by selectively targeting the agents to the AR-expressing cancer cells. These agents, either alone or in a composition, are thus useful for treating, delaying the progression of, treating the recurrence of, suppressing, inhibiting or reducing the incidence of cancers characterized by the presence of AR-expressing cells, such as prostate cancer. Accordingly, the present invention provides a) methods of selectively killing an (AR)-expressing cancer, cell; b) methods of inducing apoptosis in an (AR) expressing cancer cell; c) methods of treating a cancer characterized by the presence of AR-expressing cells in a subject; d) methods of delaying the progression of a cancer characterized by the presence of AR-expressing cells in a subject; e) methods of treating the recurrence of a cancer characterized by the presence of AR-expressing cells in a subject; f) methods of suppressing, inhibiting or reducing the incidence of a cancer characterized by the presence of'AR-expressing cells in a subject; and g) methods of treating metastasis of a cancer characterized by the presence of AR.-expressing cells in a subject; by administering to the subject or by contacting the cancer cells with a compound comprising an androgen receptor, ligand moiety and an alkylating moiety, such as the novel compounds described herein.
摘要翻译：本发明涉及一种新型的抗癌化合物，其选择性靶向表达癌症的雄激素受体（AR），诸如前列腺癌细胞和乳腺癌细胞的细胞。这些药物包含雄激素受体（AR）结合部分，其中选择性地将化合物引向表达（AR）的癌细胞，以及细胞毒性烷基化部分，例如氮芥部分。某些癌症如前列腺癌和乳腺癌中雄激素受体的固有高密度表达是因此用作选择性地增加细胞毒性化合物如烷化剂的细胞内浓度的工具，例如， DNA烷化剂，通过选择性将靶向靶向表达AR的癌细胞。因此，单独或组合物中的这些药物可用于治疗，延缓进展，治疗复发，抑制，抑制或降低以表达AR的细胞如前列腺癌为特征的癌症的发病率。因此，本发明提供：a）选择性地杀死（AR）表达的癌症，细胞; b）在（AR）表达癌细胞中诱导凋亡的方法; c）治疗特征为在受试者中存在表达AR的细胞的癌症的方法; d）延迟在受试者中以表达AR的细胞存在为特征的癌症进展的方法; e）治疗特征为在受试者中存在表达AR的细胞的癌症复发的方法; f）抑制，抑制或降低癌症发生率的方法，其特征在于在受试者中存在α表达细胞; 和g）治疗癌症转移的方法，其特征在于在受试者中存在表达AR的细胞; 通过对受试者施用或通过使癌细胞与包含雄激素受体，配体部分和烷基化部分的化合物例如本文所述的新化合物接触。

2. 发明申请

WO2004035739A3 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS 审中-公开
标题翻译：用SARMS治疗老年男性（ADAM）相关病症的雄激素降低
公开(公告)号：WO2004035739A3
公开(公告)日：2004-09-30
申请号：PCT/US0332513
申请日：2003-10-14
申请人： GTX INC , DALTON JAMES T , MILLER DUANE D , STEINER MITCHELL S , VEVERKA KAREN A
发明人： DALTON JAMES T , MILLER DUANE D , STEINER MITCHELL S , VEVERKA KAREN A
IPC分类号： C07K14/72 , A61K31/165 , A61K31/40 , A61K31/41 , A61K31/435 , A61K31/44
CPC分类号： C07K14/721
摘要： The present invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of an Androgen Decline in Aging Male (ADAM)- associated condition in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof. The present invention further provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, benign prostate hyperplasia or prostate cancer due to ADAM in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof.
摘要翻译：本发明提供了通过向受试者施用选择性雄激素受体调节剂（SARM）化合物来治疗，预防，抑制，抑制或减少男性受试者中老化雄性（ADAM）相关病症中雄激素降低的发生的方法和/或其类似物，衍生物，异构体，代谢物，药学上可接受的盐，药物产品，水合物，N-氧化物，前药，多晶型物，晶体或其任何组合。本发明进一步提供治疗，预防，抑制，抑制或减少性功能障碍，性欲减退，勃起功能障碍，性腺机能减退症，肌肉减少症，骨质减少症，骨质疏松症，认知和情绪改变，抑郁症，贫血症，脱发（SARM）化合物和/或其类似物，衍生物，异构体，代谢物，药学上可接受的盐，药物产品或药物产品给予受试者，所述受试者是男性受试者中由于ADAM引起的肥胖，良性前列腺增生或前列腺癌。水合物，N-氧化物，前药，多晶型物，晶体或其任何组合。

3. 发明申请

WO2006010162A2 COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS, AND SERMs AND METHODS OF USE THEREOF 审中-公开
标题翻译：包含5-ALPHA还原酶抑制剂的组合物及其使用方法
公开(公告)号：WO2006010162A2
公开(公告)日：2006-01-26
申请号：PCT/US2005025840
申请日：2005-07-21
申请人： GTX INC , STEINER MITCHELL S , VEVERKA KAREN A , MILLER DUANE D
发明人： STEINER MITCHELL S , VEVERKA KAREN A , MILLER DUANE D
IPC分类号： A61K31/138 , A61K31/47
CPC分类号： A61K31/138 , A61K31/47 , A61K31/56 , A61K45/06 , A61K2300/00
摘要： This invention provides for combinations of 5 alpha reductase inhibitors and SERMs. These combinations are useful in: 1) preventing prostate carcinogenesis in a subject; 2) preventing the recurrence of, suppressing, inhibiting or reducing the incidence of prostate carcinogenesis in a subject; 3) treating a subject with prostate cancer; 4) suppressing, inhibiting or reducing the incidence of prostate cancer in a subject; 5) treating a subject with pre-malignant lesions of prostate cancer; 6) suppressing, inhibiting or reducing the incidence of pre-malignant lesions of prostate cancer in a subject; 7) reducing the incidence, inhibiting, suppressing, preventing and/or treating androgen-deprivation induced conditions in men suffering from prostate cancer, such as androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), hot flashes and/or gynecomastia.; and 8) treating polycystic ovarian syndrome and reducing the incidence, inhibiting, suppressing, preventing and/or treating diabetes, cardiovascular disease, breast cancer and endometrial cancer in women suffering from polycystic ovarian syndrome.
摘要翻译：本发明提供了5种α还原酶抑制剂和SERMs的组合。这些组合可用于：1）预防受试者的前列腺癌发生; 2）预防受试者中前列腺癌发生发生的复发，抑制或降低; 3）用前列腺癌治疗受试者; 4）抑制或抑制受试者前列腺癌的发生率; 5）用前列腺癌的恶性前病变治疗受试者; 6）抑制，抑制或降低患者前列腺癌恶变前病变的发生率; 7）降低患有前列腺癌的男性的雄激素剥夺诱导的骨质疏松症，骨折，骨矿物质密度（BMD），潮热的闪烁和/或损伤的发生，抑制，抑制，预防和/或治疗雄激素剥夺诱导的病症 /或男子母乳喂养和8）治疗多囊卵巢综合征，降低发生，抑制，抑制，预防和/或治疗患有多囊卵巢综合症的妇女的糖尿病，心血管疾病，乳腺癌和子宫内膜癌。

4. 发明申请

WO2004062612A3 LARGE-SCALE SYNTHESIS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS 审中-公开
标题翻译：选择性雄激素受体调节剂的大规模合成
公开(公告)号：WO2004062612A3
公开(公告)日：2004-11-04
申请号：PCT/US2004000618
申请日：2004-01-12
申请人： GTX INC , STEINER MITCHELL S , CHUNG KIWON , DALTON JAMES , MILLER DUANE D , VEVERKA KAREN A
发明人： STEINER MITCHELL S , CHUNG KIWON , DALTON JAMES , MILLER DUANE D , VEVERKA KAREN A
IPC分类号： C07C231/12 , C07C235/24 , C07C231/00
CPC分类号： C07C231/12 , C07C235/24
摘要： The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, and alterations in mood and cognition; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity and endometriosis, d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen replacement; g) preventing and/or treating dry eye conditions; h) treatment and/or prevention of begnin prostate hyperplasia (BPH); I) inducing apoptosis in a cancer cell; j) treatment and/or prevention of cancers of female sexual organs such as breast cancer, uterine cancer and ovarian cancer; and/or other clinical therapeutic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.
摘要翻译：本发明涉及一种制备新型雄激素受体靶向剂（ARTA）的合成方法，其显示了雄激素受体的非甾体配体的雄激素和合成代谢活性。这些药物定义了一种新的亚类化合物，它们是选择性雄激素受体调节剂（SARM），其可用于a）男性避孕; b）治疗多种激素相关病症，例如与衰老男性（ADAM）中的雄激素降低相关的病症，例如疲劳，抑郁症，性欲减退，性功能障碍，勃起功能障碍，性腺机能减退，骨质疏松症，脱发，贫血，肥胖症，肌肉减少症，骨质减少症，骨质疏松症以及情绪和认知改变; c）治疗与女性雄激素降低（ADIF）有关的病症，例如性功能障碍，性欲减退，性腺机能减退，肌肉减少症，骨质减少，骨质疏松症，认知和情绪改变，抑郁症，贫血，脱发，肥胖症和子宫内膜异位症，d ）治疗和/或预防慢性肌肉消瘦; e）降低前列腺癌的发病率，停止或导致其消退; f）口服雄激素替代物; g）预防和/或治疗干眼症; h）治疗和/或预防begnin前列腺增生（BPH）; I）诱导癌细胞凋亡; j）治疗和/或预防女性性器官的癌症，如乳腺癌，子宫癌和卵巢癌; 和/或其他临床治疗和/或诊断领域。本发明的方法适用于大规模制备，因为所有步骤产生高纯度化合物，因此避免了复杂的纯化程序，最终降低了收率。因此，本发明提供了用于合成非甾体激动剂化合物的方法，其可以用于工业大规模合成，并且以高收率提供高纯度产物。

5. 发明申请

WO03065992A2 TREATING BENIGN PROSTATE HYPERPLASIA WITH SARMS 审中-公开
标题翻译：用SARMS处理BENIGN PROSTATE HYPERPLASIA
公开(公告)号：WO03065992A2
公开(公告)日：2003-08-14
申请号：PCT/US0303447
申请日：2003-02-06
申请人： GTX INC , STEINER MITCHELL S , VEVERKA KAREN A , MILLER DUANE D , DALTON JAMES T , CHUNG KIWON , GAO WENQING
发明人： STEINER MITCHELL S , VEVERKA KAREN A , MILLER DUANE D , DALTON JAMES T , CHUNG KIWON , GAO WENQING
IPC分类号： A61K45/00 , A61K31/00 , A61K31/167 , A61K31/277 , A61K31/56 , A61P13/08 , A61P43/00 , A61K
CPC分类号： A61K31/277 , A61K31/00 , A61K31/167 , A61K31/56
摘要： This invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of benign prostate hyperplasia in a male subject, by administering to the subject a selective androgen receptor modulator(SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of treating a subject suffering from hair loss, comprising the step of administering to the subject a therapeutically effective amount of a 5-a reductase enzyme type 1 and /or type 2 inhibitor, wherein said inhibitor is a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite,pharmaceutically acceptable salt, pharmaceutical product, hydrate, Woxide, or any combination thereof as described herein. This invention also provides a method of inhibiting a 5-a reductase type 1 and/or type 2 enzyme, comprising contacting the enzyme with an effective 5-a reductase inhibitory amount of a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, as described herein.
摘要翻译：本发明提供了通过向受试者施用选择性雄激素受体调节剂（SARM）和/或其类似物，衍生物，异构体，代谢物来治疗，预防，抑制或降低男性患者良性前列腺增生的发生率的方法，药学上可接受的盐，药物产品，水合物，N-氧化物或其任何组合。本发明还提供了一种治疗脱发患者的方法，包括向受试者施用治疗有效量的1型和/或2型抑制剂的5-a还原酶的步骤，其中所述抑制剂是选择性雄激素受体调节剂（SARM）和/或其类似物，衍生物，异构体，代谢物，药学上可接受的盐，药物产品，水合物，氧化物或其任何组合。本发明还提供抑制1型和/或2型5α还原酶的方法，包括使酶与有效的5-a还原酶抑制量的选择性雄激素受体调节剂（SARM）和/或其类似物接触，衍生物，异构体，代谢物，药学上可接受的盐，药物产品，水合物，N-氧化物或其任何组合。

6. 发明申请

WO2007081696A2 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS 审中-公开
标题翻译：治疗老年男性（ADAM）的SARS治疗条件恶化
公开(公告)号：WO2007081696A2
公开(公告)日：2007-07-19
申请号：PCT/US2007000052
申请日：2007-01-04
申请人： GTX INC , DALTON JAMES T , MILLER DUANE D , STEINER MITCHELL S , VEVERKA KAREN A
发明人： DALTON JAMES T , MILLER DUANE D , STEINER MITCHELL S , VEVERKA KAREN A
IPC分类号： A61K31/277 , C07K14/72
CPC分类号： A61K31/277 , C07K14/721
摘要： This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and/or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof.
摘要翻译：本发明提供了用于治疗和抑制雄性雄性雄激素降低（ADAM）相关病症的男性受试者的方法，例如性功能障碍，性欲性降低，勃起功能障碍，性腺机能减退，肌肉减少症，骨质减少症，骨质疏松症，认知改变通过向受试者施用选择性雄激素受体调节剂（SARM）化合物和/或其类似物，通过向受试者施用选择性雄激素受体调节剂（SARM）化合物和/或其类似物，衍生物，异构体，代谢物，药学上可接受的盐，药物产品，水合物，N-氧化物，前药，多晶型物，晶体或其任何组合。

7. 发明申请

WO2004066922A3 A METHOD OF TREATING BREAST CANCER WITH ANDROGEN RECEPTOR ANTAGONISTS 审中-公开
标题翻译：一种用雄激素受体拮抗剂治疗乳腺癌的方法
公开(公告)号：WO2004066922A3
公开(公告)日：2005-09-15
申请号：PCT/US2004001313
申请日：2004-01-20
申请人： GTX INC , STEINER MITCHELL S , DALTON JAMES T , MILLER DUANE D , VEVERKA KAREN A
发明人： STEINER MITCHELL S , DALTON JAMES T , MILLER DUANE D , VEVERKA KAREN A
IPC分类号： A61K20060101 , A61K31/165 , A61K31/21 , A61K31/26 , A61K31/277 , A61K31/32 , A61K31/66 , A61P35/00
CPC分类号： A61K31/66 , A61K31/21 , A61K31/26
摘要： This invention relates to the prevention and treatment of breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of a) treating a subject suffering from breast cancer; b) preventing, suppressing, inhibiting or reducing the incidence of breast cancer in a subject; c) delaying the progression of breast cancer in a subject suffering from breast cancer; d) preventing the recurrence of breast cancer in a subject; e) treating the recurrence of breast cancer in a subject suffering from breast cancer; and/or f) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer, by administering to the subject a therapeutically effective amount of an Androgen Receptor Antagonist and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, phatmaceutical product, hydrate, N-Oxide, crystal polymorph, prodrug or any combination thereof, as described herein.
摘要翻译：本发明涉及预防和治疗受试者，例如女性受试者的乳腺癌。因此，本发明提供了a）治疗患有乳腺癌的受试者的方法; b）预防，抑制，抑制或降低患者乳腺癌的发生率; c）延缓乳腺癌患者乳腺癌的进展; d）预防受试者乳腺癌的复发; e）治疗乳腺癌患者乳腺癌的复发; 和/或f）通过向受试者施用治疗有效量的雄激素受体拮抗剂和/或其类似物，衍生物，异构体，代谢物，药学上可接受的盐，治疗，预防，抑制或抑制患有乳腺癌的受试者的转移，药物产品，水合物，N-氧化物，晶体多晶型物，前药或其任何组合。

8. 发明申请

WO2005060647A3 PRODRUGS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF 审中-公开
标题翻译：选择性受体调节剂的制备及其使用方法
公开(公告)号：WO2005060647A3
公开(公告)日：2005-09-01
申请号：PCT/US2004042097
申请日：2004-12-16
申请人： GTX INC , MILLER DUANE D , STEINER MITCHELL S , VEVERKA KAREN A
发明人： MILLER DUANE D , STEINER MITCHELL S , VEVERKA KAREN A
IPC分类号： A01N55/04 , C07C233/05 , C07F9/09
CPC分类号： C07F9/091 , A61K31/4704 , A61K47/548 , C07C235/24
摘要： The present invention provides prodrugs of selective androgen receptor modulators (SARMs), and their use in treating or reducing the incidence of osteoporosis, a variety of hormone-related conditions, conditions associated with Androgen Decline in Aging Male (ADAM); conditions associated with Androgen Decline in Female (ADIF), and muscular wasting conditions, obesity, dry eye conditions, and prostate cancer. The prodrugs are also useful in oral and androgen replacement therapy and male contraception.
摘要翻译：本发明提供选择性雄激素受体调节剂（SARM）的前药，以及它们在治疗或降低骨质疏松症发生率，多种激素相关病症，与老年男性（ADAM）雄激素衰退相关的病症中的用途。与雄激素降低（ADIF）相关的病症，肌肉消瘦症，肥胖症，干眼症状和前列腺癌。前药还可用于口服和雄激素替代疗法和男性避孕。

9. 发明申请

WO2004064747A2 TREATING ANDROGEN DEFICIENCY IN FEMALE (ADIF)-ASSOCIATED CONDITIONS WITH SARMS 审中-公开
标题翻译：女性（ADIF）治疗SARS治疗条件缺陷
公开(公告)号：WO2004064747A2
公开(公告)日：2004-08-05
申请号：PCT/US2004001359
申请日：2004-01-20
申请人： GTX INC , STEINER MITCHELL S , VEVERKA KAREN A , DALTON JAMES T , MILLER DUANE D
发明人： STEINER MITCHELL S , VEVERKA KAREN A , MILLER DUANE D
IPC分类号： A61K20060101 , A61K31/165 , A61K31/166 , A61K31/195 , A61K31/22 , A61K31/277 , A61K31/66 , A61K
CPC分类号： A61K31/22 , A61K31/166
摘要： The present invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of an Androgen Deficiency in Female (ADIF)-associated condition in a female subject, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug, or any combination thereof. The present invention further provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, fatigue, depression, anemia, muscle weakness, hair loss, obesity, polycystic ovarian disease, endometriosis, breast cancer, uterine cancer and ovarian cancer due to ADIF in a female subject, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug, or any combination thereof.
摘要翻译：本发明提供了通过向受试者施用选择性雄激素受体调节剂（SARM）化合物和治疗雌激素受体调节剂（SARM）化合物的方法来治疗，预防，抑制，抑制或降低女性受试者中雄激素缺乏症（ADIF）相关病症的发生率或其类似物，衍生物，异构体，代谢物，药学上可接受的盐，药物产品，水合物，N-氧化物，晶体，多晶型物，前药或其任何组合。本发明还提供一种治疗，预防，抑制或降低性功能障碍，性欲降低，性腺机能减退，肌肉减少症，骨质减少症，骨质疏松症，认知和情绪改变，疲劳，抑郁，贫血，肌肉无力等的发生的方法，通过向受试者施用选择性雄激素受体调节剂（SARM）化合物和/或其类似物，衍生物异构体，通过对雌性受试者的ADIF引起的脱发，肥胖，多囊卵巢疾病，子宫内膜异位症，乳腺癌，子宫癌和卵巢癌，代谢物，药学上可接受的盐，药物产品，水合物，N-氧化物，晶体，多晶型物，前药或其任何组合。

10. 发明申请

WO2005037201A3 TREATING BONE-RELATED DISORDERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS 审中-公开
标题翻译：用选择性的雄激素受体调节剂治疗骨骼相关疾病
公开(公告)号：WO2005037201A3
公开(公告)日：2005-10-06
申请号：PCT/US2004033395
申请日：2004-10-12
申请人： GTX INC , DALTON JAMES , MILLER DUANE D , STEINER MITCHELL S , VEVERKA KAREN A , KEARBY JEFFREY
发明人： DALTON JAMES , MILLER DUANE D , STEINER MITCHELL S , VEVERKA KAREN A , KEARBY JEFFREY
IPC分类号： A61K20060101 , C07F7/22
CPC分类号： A61K31/167 , A61K31/00 , A61K31/165 , A61K31/21 , A61K31/32 , A61K31/405 , A61K31/4704 , A61K31/66
摘要： This invention provides method of treating, preventing, suppressing, inhibiting, or reducing the risk of developing a bone-related disorder, for example osteoporosis, osteopenia, increased bone resorption, bone fracture, bone frailty and/or loss of bone mineral density (BMD), by administrating a therapeutically effective amount of a selective androgen receptor modulator (SARM) and/or its analogue, derivative, isomer, metabolite pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof. The invention also provides methods of decreasing fat mass (FM) and increasing lean mass, comprising administering same.
摘要翻译：本发明提供了治疗，预防，抑制，抑制或降低骨相关病症发生风险的方法，例如骨质疏松症，骨质减少，增加的骨吸收，骨折，骨质脆弱和/或骨矿物质密度的丧失（BMD ），通过施用治疗有效量的选择性雄激素受体调节剂（SARM）和/或其类似物，衍生物，异构体，代谢物药学上可接受的盐，药物产品，水合物，N-氧化物或其任何组合。本发明还提供降低脂肪量（FM）和增加瘦肉质量的方法，包括施用它们。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式